Inflammatory stress due to infection by various micro-organisms is known to activate the hypothalamo-pituitary-adrenocortical (HPA) axis through inflammatory mediators. Recently, pituitary-adenylate-cyclase-activating polypeptide (PACAP) was shown to be located in corticotropin-releasing factor containing neurons of the medial parvocellular part of the hypothalamic paraventricular nucleus (mpPVN). In the present study, we demonstrate that PACAP gene expression is induced in neurons of the mpPVN after intraperitoneal administration of bacterial lipopolysaccharide (LPS) which was accompanied by a marked increase in PACAP immunoreactivity in the external zone of the median eminence. As determined by quantitative in situ hybridization, PACAP gene expression was rapidly induced after 4 h and was elevated for 48 h, declining to normal levels after 72 h. A significant increase in PACAP mRNA was also observed following intraperitoneal injection of interleukin-1β. PACAP gene expression was not induced by LPS in vagotomized animals, suggesting that the increase in PACAP mRNA following immune activation by LPS is mediated via the vagus nerve. The findings suggest that PACAP may function as a hypothalamo-pituitary-releasing factor during acute inflammation.

Keywords:
Lipopolysaccharide, Vagotomy, Cytokines, Immunocytochemistry, In situ hybridization, Paraventricular nucleus, Interleukins, Pituitary adenylate-cyclase-activating polypeptide, Neuroimmune interactions, Adrenal steroids
1.
Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394–1397.
2.
Rivest S, Rivier C: Influence of the paraventricular nucleus of the hypothalamus in the alteration of neuroendocrine functions induced by intermittent footshock or interleukin. Endocrinology 1991;129:2049–2057.
3.
Rivier C: Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis of the rat. Ann NY Acad Sci 1993;697:97–105.
4.
Dunn AJ: Infection as a stressor: A cytokine-mediated activation of the hypothalamo-pituitary-adrenal axis? Ciba Found Symp 1993;172:226–239.
5.
Dunn AJ: The role of interleukin-1 and tumor necrosis factor alpha in the neurochemical and neuroendocrine responses to endotoxin. Brain Res Bull 1992;29:807–812.
6.
Dunn AJ: Role of cytokines in infection-induced stress. Ann NY Acad Sci 1993;697:189–202.
7.
Rivier C, Rivest S: Mechanisms mediating the effects of cytokines on neuroendocrine functions in the rat. Ciba Found Symp 1993;172:204–220.
8.
Harbuz MS, Lightman SL: Stress and the hypothalamo-pituitary-adrenal axis: Acute, chronic and immunological activation. J Endocrinol 1992;134:327–339.
9.
Antoni FA: Hypothalamic control of adrenocorticotropin secretion: Advance since the discovery of 41-residue corticotropin-releasing factor. Endocrine Rev 1986;7:351–378.
10.
Gillies GE, Linton EA, Lowry PJ: Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 1982;229:355–357.
11.
Schmidt ED, Janszen AW, Wouterlood FG, Tilders FJ: Interleukin-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)-neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis. J Neurosci 1995;15:7417–7426.
12.
Schmidt ED, Binnekade R, Janszen AW, Tilders FJ: Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. J Neuroendocrinol, 1996;8:703–712.
13.
Arimura A, Shioda S: Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: Neuroendocrine and endocrine interaction. Front Neuroendocrinol 1995;16:53–88.
14.
Hannibal J, Mikkelsen JD, Fahrenkrug J, Larsen PJ: Pituitary adenylate cyclase-activating peptide gene expression in corticotropin-releasing factor-containing parvicellular neurons of the rat hypothalamic paraventricular nucleus is induced by colchicine, but not by adrenalectomy, acute osmotic, ether, or restraint stress. Endocrinology 1995;136:4116–4124.
15.
Ceccatelli S, Villar MJ, Goldstein M, Hökfelt T: Expression of c-fos immunoreactivity in transmitter characterized neurons after stress. Proc Natl Acad Sci USA 1989;86:9569–9573.
16.
Gaykema RP, Dijkstra I, Tilders FJ: Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion. Endocrinology 1995;136:4717–4720.
17.
Tilders FJ, DeRijk RH, Van Dam AM, Vincent VA, Schotanus K, Persoons JH: Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: Routes and intermediates signals. Psychoneuroendocrinol 1994;19:209–232.
18.
Zuckerman SH, Shellhaas J, Butler LD: Differential regulation of lipopolysaccaride-induced interleukin-1 and tumor necrosis factor-alpha synthesis: Effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 1989;19:301–305.
19.
Harbuz MS, Rees RG, Eckland DJ, Jessop DS, Brewerton D, Lightman SL: Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress. Endocrinology 1992;130:1394–1400.
20.
Shinmei M, Masuda K, Kikushi T, Shinomura Y: Interleukin 1, tumor necrosis factor and interleukin 6 as mediators of cartilage destruction. Semin Arthritis Rheum 1989;(18(suppl):27–31.
21.
Leisten JC, Gaarde WA, Scholz W: Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin. Clin Immunol Immonopathol 1990;56:108–114.
22.
Watkins LR, Wiertelak EP, Goehler LE, Mooney-Heiberger K, Martinez J, Furness L, Smith KP, Maier SF: Neurocircuitry of illness-induced hyperalgesia. Brain Res 1994;639:283–299.
23.
Hannibal J, Mikkelsen JD, Clausen H, Holst JJ, Wulff BS, Fahrenkrug J: Gene expression of pituitary adenlyate cyclase activating polypeptide (PACAP) in the rat hypothalamus. Regul Pept 1995;55:133–148.
24.
Hannibal J, Ding JM, Chen D, Gillette MU, Fahrenkrug J, Larsen PJ, Mikkelsen JD: Pituitary adenylate cyclase activating peptide (PACAP) in the retinohypothalamic tract. A daytime regulator of the biological clock. J Neurosci 1997;17:2637–2644.
25.
Fahrenkrug J, Hannibal J: PACAP immunoreactivity in capsaicin-sensitive nerve fibers supplying the rat urinary tract. Neuroscience 1998;83:1261–1272.
26.
Chover-Gonzalez AJ, Harbuz MS, Lightman SL: Effect of adrenalectomy and stress on interleukin-1 beta-mediated activation of hypothalamic corticotropin-releasing factor mRNA. J Neuroimmunol 1993;42:155–160.
27.
Harbuz MS, Stephanou A, Sarlis N, Lightman SL: The effects of recombinant human interleukin (IL)-1 alpha, IL-1 beta or IL-6 on hypothalamo-pituitary-adrenal axis activation. J Endocrinol 1992;133:349–355.
28.
Rivest S, Laflamme N: Neuronal activity and neuropeptide gene transcription in the brains of immune-challenged rats. J Neuroendocrinol 1998;7:501–525.
29.
Rivest S, Laflamme N, Nappi RE: Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci 1995;15:2680–2695.
30.
Dow RC, Bennie J, Fink G: Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol 1994;142:R1–R4.
31.
Rawlings SR, Hezareh M: Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: Actions on the anterior pituitary gland. Endocr Rev 1996;17:4–29.
32.
Gottschall PE, Tatsuno I, Miyata A, Arimura A: Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 1990;127:272–277.
33.
Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L: Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993;365:170–175.
34.
Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH: Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989;164:567–574.
35.
Propato Mussafiri R, Kanse SM, Ghatei MA, Bloom SR: Pituitary adenylate cycylase-activating polypeptide releases 7B2, adrenocorticotrophin, growth hormone and prolactin from the mouse and rat clonal pituitary cell lines AtT-20 and GH3. J Endocrinol 1992;132:107–113.
36.
Chiodera P, Volpi R, Capretti L, Caffarri G, Magotti MG, Coiro V: Effects of intravenously infused pituitary adenylate cyclase activating polypeptide on adenohypophyseal hormone secretion in normal men. Neuroendocrinology 1996;64:242–246.
37.
Grinevich V, Fournier A, Pelletier G: Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotropin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus. Brain Res 1997;773:190–196.
38.
Legradi G, Hannibal J, Lechan RM: Pituitary adenylate cyclase-activating polypeptide-nerve terminals densely innervate corticotropin-releasing hormone-neurons in the hypothalamic paraventricular nucleus of the rat. Neurosci Lett 1998;246:145–148.
39.
Nomura M, Ueta Y, Serino R, Kabashima N, Shibuya I, Yamashita H: PACAP type I receptor gene expression in the paraventricular and supraoptic nuclei of rats. NeuroReport 1996;8:67–70.
40.
Hashimoto H, Nogi H, Mori K, Ohishi H, Shigemoto R, Yamamoto K, Matsuda T, Mizuno N, Nagata S, Baba A: Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: An in situ hybridization study. J Comp Neurol 1996;371:567–577.
41.
Banks WA, Ortiz L, Plotkin SR, Kastin AJ: Human interleukin (IL) 1α, murine IL-1α and murine IL-1β are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 1991;259:988–996.
42.
Hansen MK, Taishi P, Chen Z, Krueger JM: Vagotomy blocks the induction of interleukin-1beta (IL-1beta) mRNA in the brain of rats in response to systemic IL-1beta. J Neurosci 1998;18:2247–2253.
43.
Hansen MK, Krueger JM: Subdiaphragmatic vagotomy blocks the sleep- and fever-promoting effects of interleukin-1beta. Am J Physiol 1997;273:R1246–R1253.
44.
Romanovsky AA, Simons CT, Szekely M, Kulchitsky VA: The vagus nerve in the thermoregulatory response to systemic inflammation. Am J Physiol 1997;273:R407–R413.
45.
Fleshner M, Silbert L, Deak T, Goehler LE, Martin D, Watkins LR, Maier SF: TNF-alpha-induced corticosterone elevation but not serum protein or corticosteroid binding globulin reduction is vagally mediated. Brain Res Bull 1997;44:701–706.
46.
Milligan ED, McGorry MM, Fleshner M, Gaykema RP, Goehler LE, Watkins LR, Maier SF: Subdiaphragmatic vagotomy does not prevent fever following intracerebroventricular prostaglandin E2: Further evidence for the importance of vagal afferents in immune-to-brain communication. Brain Res 1997;766:240–243.
47.
Goehler LE, Relton JK, Dripps D, Kiechle R, Tartaglia N, Maier SF, Watkins LR: Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: A possible mechanism for immune-to-brain communication. Brain Res Bull 1997;43:357–364.
48.
Ericsson A, Kovacs KJ, Sawchenko PE: A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 1994;14:897–913.
49.
Ericsson A, Arias C, Sawchenko PE: Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 1997;17:7166–7179.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.